The scale of the discrepancy is easiest to see with the glucagon-like peptide-1 receptor agonists, the class of drugs behind the global weight-loss revolution. A recent synthesis of real-world evidence found that between 20 and 50 percent of patients discontinue GLP-1 receptor agonists within the first year. Many who stay on treatment use substantially lower doses than those studied in trials, and the weight loss observed in clinical practice is consistently lower than in randomized controlled trials. Crucially, among highly adherent patients, outcomes approach the trial results, which suggests the drugs themselves are not the problem. The drivers of early discontinuation are familiar ones: gastrointestinal side effects, cost, insurance barriers, and supply shortages that have repeatedly left pharmacies without stock.

The consequences of stopping, however, are not uniform, and this is where the stakes become far higher than a number on a bathroom scale. For patients prescribed GLP-1 receptor agonists solely for weight management, discontinuation primarily results in weight regain. But the same drugs also reduce the risk of cardiovascular events and clinically important kidney disease outcomes compared with placebo. Because these protective benefits depend on continued exposure to the drug rather than conferring durable protection after withdrawal, a patient who stops treatment forfeits not only the weight loss but also reductions in morbidity and mortality. The prescription, in other words, is a subscription to benefit, and cancellation carries a clinical price.

A similar shortfall appears with anticoagulants, medications whose value is about as unambiguous as it gets. A systematic review and meta-analysis of nearly 595,000 patients with atrial fibrillation found that only two-thirds maintained good adherence to direct oral anticoagulants, the modern stroke-preventing drugs that require far less monitoring than their predecessor warfarin. Among those who did not adhere, the risk of stroke increased by 39 percent. That finding quantifies the distance between prescribed therapy and delivered benefit even for medications with straightforward dosing, and it reframes nonadherence from a vague behavioral concern into a measurable contributor to preventable strokes and deaths.

A different kind of adherence failure is unfolding with the recombinant zoster vaccine, which protects against shingles and requires only two doses separated by two to six months. A nationwide study of more than 726,000 US adults found that adherence to the recommended schedule was just 72 percent, with completion rates markedly lower among racial and ethnic minorities, younger adults, and people with lower household income. What makes this particularly consequential is emerging evidence about what the vaccine might do beyond preventing a painful rash. A large-scale longitudinal analysis of US health records found that herpes zoster vaccination was associated with a reduced risk of dementia, with stronger protection in people who received both doses of the recombinant vaccine compared with a single dose. A target trial emulation among nearly 510,000 skilled-nursing facility residents similarly found the vaccine was associated with reduced dementia risk. If these findings are confirmed by ongoing trials, every person who fails to complete the two-dose series may be forgoing not only protection against shingles but a potential modification of dementia risk.

The underlying problem itself has barely changed in fifty years of research, and that is precisely the point. Marcum’s argument centers on the opportunity cost of nonadherence, the benefit forgone when effective therapy goes untaken. The logic is straightforward: when adherence rates stay static while treatment effects grow, the benefit lost through nonadherence grows with them. The numbers illustrate the leap in therapeutic power. In a network meta-analysis, semaglutide reduced body weight by 11.4 percent from baseline compared with 3.1 percent for the older drug orlistat. Direct oral anticoagulants reduce stroke or systemic embolism by 19 percent compared with warfarin. The recombinant zoster vaccine cuts shingles risk by 92 percent, versus 51 percent for its live attenuated predecessor. But these benefits are realized only under the conditions of trial participation, where drugs are free and adherence is monitored. In practice, where patients bear cost-sharing and juggle competing demands, the attenuation of benefit is substantial.

The economics of the problem are genuinely awkward. With therapies costing tens of thousands of dollars per year, improving adherence increases short-term expenditures, a tension that makes payers uneasy even though the downstream costs of preventable hospitalizations and disease progression are far greater. Nonadherence itself is also heterogeneous, ranging from cost-related gaps in treatment to unintentional lapses in complex regimens, and effective solutions must account for that variation. Nor is every discontinuation a failure. Stopping a therapy after an informed discussion of adverse effects with a healthcare provider is shared decision-making, and conflating it with nonadherence distorts both research and policy.

What can be done? Established interventions such as patient education, simpler dosing schedules, and improved communication remain necessary but demonstrably insufficient. A Cochrane review of 182 randomized trials found that even the most effective adherence interventions, typically bundles of education, counseling, and ongoing support from health system professionals, produced only modest improvements in adherence or clinical outcomes. At the bedside, clinicians can treat adherence as a clinical decision point: counseling patients on the cardiorenal benefits at risk when a GLP-1 receptor agonist is stopped, checking persistence at every anticoagulant renewal, and stressing the importance of completing the vaccine series. But individual effort has limits, and the evidence says those limits arrive quickly.

That is why Marcum calls for a system-level reconceptualization of adherence as a determinant of therapeutic value, meaning interventions that change the environment in which prescriptions are written, filled, and consumed. For GLP-1 receptor agonists, that means addressing the structural barriers of cost, insurance coverage, and supply that drive discontinuation. For chronic medications, it means expanding pharmacists’ authority to manage therapy through collaborative practice agreements and transition-of-care programs, and aligning cost-sharing with therapeutic value through value-based insurance design. For multi-dose vaccines, it means integrating completion tracking into electronic health records. The proof that such approaches can work already exists: a randomized trial of nearly 6,000 patients after myocardial infarction eliminated copayments for cardiovascular medications, improving adherence by 4 to 6 percent and reducing rates of first major vascular events without increasing total health spending.

Compounding everything is the fact that nonadherence is hard to detect in routine practice. Clinicians consistently underestimate it, and the available measures, including pharmacy refill records, self-report, and electronic health record documentation, each capture only a partial picture. Artificial intelligence may eventually help close this detection gap, though rigorous evidence that such tools improve clinically meaningful endpoints remains limited. The bottom line, Marcum argues, is that the limiting factor in realizing the full value of modern therapeutics is no longer only pharmacology; it is human behavior, reinforced by systems that make adherence difficult. Until the same rigor applied to drug discovery is applied to coverage design, pharmacist-led programs, health information technology, and implementation research, medicine will keep paying for the promise of transformative therapies while realizing only a fraction of their benefit.

Subject of Research: Medication nonadherence and the widening gap between clinical trial efficacy and real-world effectiveness

Article Title: The widening medication adherence gap

Article References: Marcum, Z. A. (2026). The widening medication adherence gap. PLOS Medicine, 23(9), e1005237. https://doi.org/10.1371/journal.pmed.1005237

Image Credits: AI Generated

DOI: 10.1371/journal.pmed.1005237

Keywords: medication adherence, GLP-1 receptor agonists, anticoagulants, herpes zoster vaccine, dementia risk, obesity treatment, stroke prevention, health systems, value-based insurance design, pharmacist-led programs, PLOS Medicine, real-world evidence

The medial temporal lobe, encompassing the entorhinal cortex and hippocampus, is where Alzheimer’s pathology takes root. Tau tangles appear here earlier than anywhere else in the brain, and the density of these misfolded filaments tracks closely with the episodic memory failures that define the disease. Yet while the link between neocortical tau and amyloid-β is well established, the relationship within the medial temporal lobe has remained murky. Positron emission tomography, the workhorse of in vivo amyloid and tau imaging, struggles in this deep, folded region because of limited spatial resolution, off-target tracer binding, and reduced sensitivity. Autopsy tissue, by contrast, allows direct, region-specific quantification of plaques and tangles, which is precisely why the researchers turned to two of the world’s most rigorously characterized brain donation programs.

The main cohort came from the Religious Orders Study and the Rush Memory and Aging Project, longitudinal studies that have followed older Catholic clergy and Chicago-area residents for decades, with 1,587 participants donating their brains at death. The replication cohort drew from the Arizona Study of Aging and Neurodegenerative Disorders, adding 963 more donors. In the main cohort, amyloid-β load was measured as the percentage of tissue area occupied by immunostained deposits, while tau was quantified as neurofibrillary tangle density using the AT8 antibody across eight cortical regions. The Arizona cohort used semi-quantitative CERAD-style grading with thioflavin-S, Campbell-Switzer, and Gallyas staining. Crucially, both datasets allowed the team to compute separate amyloid-β and tau composites for the medial temporal lobe and for the six remaining neocortical regions, and to adjust for co-pathologies including TDP-43, Lewy bodies, and vascular lesions.

The starting point was unsurprising: in both cohorts, carrying at least one APOE-ε4 allele and being female were each associated with significantly greater medial temporal tau tangle burden, with all p-values below 0.001. APOE-ε4 carriers also showed markedly higher amyloid-β in both the neocortex and the medial temporal lobe. The effects of female sex on amyloid were weaker and less consistent, reaching significance in the main cohort only. The pivotal question was what would happen when amyloid-β entered the statistical models as a potential mediator of the tau associations.

Adjusting for global neocortical amyloid-β alone attenuated both associations but did not eliminate them. The turning point came when the researchers jointly accounted for global and regional medial temporal amyloid-β. Under that fuller specification, the association between APOE-ε4 and medial temporal tau dissolved entirely, falling to non-significance in both cohorts with p-values of at least 0.19. The female sex effect, however, remained robust, with p-values of 0.004 or lower. Models incorporating both spatial scales of amyloid pathology explained substantially more variance in medial temporal tau than global measures alone, and the results held when the team additionally adjusted for diagnostic group, clinical stage, or neocortical tau burden.

Path analysis, a form of structural equation modeling that traces how effects flow through intermediate variables, sharpened the picture. The researchers ordered the pathology variables a priori according to known neuropathological staging: diffuse neocortical plaques precede neuritic plaques, neocortical amyloid precedes medial temporal amyloid, and medial temporal amyloid precedes tangles. In both cohorts, roughly three quarters of the total APOE-ε4 effect on medial temporal tau was mediated by amyloid-β, 79.5 percent in the main cohort and 74.5 percent in the replication sample, and the residual direct effect was statistically indistinguishable from zero. For female sex, less than half of the effect was amyloid-mediated, just 44.0 percent and 14.4 percent respectively, and a significant amyloid-independent component persisted in both cohorts.

Sensitivity analyses reinforced the dissociation. Among donors with no significant amyloid-β pathology on the CERAD scale, 499 in the main cohort and 211 in the replication set, APOE-ε4 showed no association with medial temporal tau at all. Female sex, meanwhile, remained significantly linked to higher tau in the main cohort and showed a strong trend in the replication sample. When the team repeated the analyses separately for the entorhinal cortex and hippocampus, and when they tested for APOE-ε4 by sex interactions, the same pattern emerged: after accounting for amyloid-β, women carried more medial temporal tau regardless of genotype.

The authors propose plausible, if unproven, mechanisms for the sex-specific vulnerability. Endocrine transitions, particularly the loss of estrogen around menopause, have been linked to tau burden in prior imaging studies, and sex differences in neuroimmune biology, including microglial activation, have been tied to both amyloid and tau pathologies. The persistence of the sex effect in amyloid-free brains and after adjustment for disease-stage proxies suggests that female-associated tau accumulation in the medial temporal lobe is at least partly an amyloid-independent process, potentially accelerating progression and amplifying tau-mediated cognitive decline. The study’s design, being cross-sectional autopsy data, cannot establish causality or temporal ordering, and the cohorts lack racial, ethnic, and socioeconomic diversity, limitations the authors acknowledge candidly.

For the APOE-ε4 story, the findings carry a more encouraging message. If the gene variant amplifies tau largely through its strong effects on amyloid-β accumulation and distribution, then the new generation of anti-amyloid therapies might, in principle, blunt the downstream tau consequences that matter most for cognition, particularly in early disease stages when localized amyloid and tau deposits fall below PET detection thresholds. The study also highlights a methodological blind spot: most in vivo studies quantify amyloid with a global neocortical composite, potentially obscuring the local amyloid-tau interplay within the medial temporal lobe that the autopsy data reveal. Whether plaque removal alters tau trajectories in a genotype-dependent manner will require longitudinal and interventional evidence that this design cannot provide.

The practical upshot is a call for precision in trial design. Post hoc analyses of some anti-amyloid trials have hinted at sex differences in treatment outcomes, though such exploratory subgroup findings were never powered for definitive interaction testing. The new results argue that sex and APOE genotype should be built into prespecified analytic plans for therapies targeting amyloid, tau, or APOE biology, rather than treated as afterthoughts. They also frame a pressing open question for the field: identifying the biological basis of women’s heightened medial temporal tau vulnerability could clarify why Alzheimer’s prevalence and progression differ by sex and open therapeutic avenues that current amyloid-centric strategies leave untouched. Until then, the autopsy bench has delivered a clear verdict, APOE-ε4 works through amyloid, and female sex, at least in part, works around it.

Subject of Research: Amyloid-β-mediated versus amyloid-independent pathways linking APOE-ε4 and female sex to medial temporal tau pathology in Alzheimer's disease

Article Title: Global and regional amyloid-β in explaining APOE-ε4 and sex associations with medial temporal tau: a neuropathology study

Article References: Salvadó, G., Groot, C., Wisse, L. E., Vogel, J. W., Beach, T. G., Serrano, G. E., Reiman, E. M., Schneider, J. A., Bennett, D. A., Ossenkoppele, R., & Hansson, O. (2026). Global and regional amyloid-β in explaining APOE-ε4 and sex associations with medial temporal tau: a neuropathology study. Acta Neuropathologica, 152(1), Article 49. https://doi.org/10.1007/s00401-026-03095-2

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03095-2

Keywords: Alzheimer's disease, APOE-ε4, tau tangles, amyloid-β, medial temporal lobe, neuropathology, sex differences, hippocampus, entorhinal cortex, brain donation, dementia risk, clinical trials

The research, led by Baptiste Perthuy and Leslie M. Decker of the COMETE laboratory at Université de Caen Normandie, together with colleagues including Nick Stergiou of the University of Nebraska at Omaha and Fabien Cignetti of the Grenoble Institute of Neurosciences, took an unusual approach. Rather than comparing group averages, the team built a normative model of healthy walking and then measured how far each individual deviated from it, domain by domain. Ninety-seven adults aged 55 and over completed two treadmill walking bouts of three minutes and thirty seconds at their preferred speed. The participants fell into three groups: twenty older adults with MCR, twenty healthy older adults with slow gait who were matched to the MCR group on demographics and walked at comparably slow speeds, and fifty-seven healthy older adults who served as the reference population.

The methodological core of the study lies in how walking was decomposed. The researchers organized a battery of linear spatiotemporal measures and nonlinear variables derived from trunk acceleration into ten functional gait domains. These were conceptually grouped into three tiers: gait pattern, covering pace, rhythm, gait phases, postural control, and symmetry; fluctuation amplitude, essentially step-to-step variability; and the temporal structure of those fluctuations, which includes regulation, signal complexity, divergence of movement trajectories, and attractor complexity. This domain-based framework reflects a growing consensus in the biomechanics literature that gait is not a single quantity but a bundle of partly independent control processes, each with its own neural substrates.

To quantify deviation, the team trained a Gaussian mixture model on data from the healthy older adults. A Gaussian mixture model is a probabilistic machine learning technique that fits a set of overlapping bell-shaped distributions to data, effectively learning the shape of normal variation in each gait domain. Once trained, the model defines a normative reference space, and any new individual can be assigned an anomaly score that expresses how improbable their gait profile is relative to that healthy distribution. This approach, borrowed from normative modeling in computational psychiatry, sidesteps a chronic weakness of case-control studies: it does not assume that a clinical group is merely shifted in the average, but instead maps each person’s position within or outside the healthy manifold.

The results split cleanly into two layers. Both the MCR group and the healthy slow walkers showed elevated deviations in gait pattern domains, specifically pace and phases, which is exactly what one would expect given their slower walking speed. In other words, the coarse, speed-related signature of gait does not distinguish MCR from ordinary age-related slowing. That finding alone is a pointed critique of gait speed as a stand-alone clinical marker: two people can walk at the same slow tempo for entirely different reasons, and a stopwatch cannot tell them apart.

The second layer is where the study becomes striking. Only the MCR group showed additional deviations in the domains related to fluctuation amplitude and temporal structure. Their walking exhibited increased step-to-step variability, and their trunk acceleration fluctuations were more divergent, more predictable, and less complex than those of healthy walkers. Each of those adjectives carries technical weight. Greater divergence of movement trajectories, typically quantified through Lyapunov exponents, indicates that small perturbations during walking grow faster over time, a hallmark of reduced local dynamic stability. Greater predictability and reduced complexity, often measured with entropy-based statistics, suggest that the gait pattern has become more rigid and stereotyped, losing the adaptive variability that characterizes healthy neuromotor control.

These nonlinear findings resonate with a theoretical framework that Stergiou and Decker helped develop more than a decade ago, which proposes that healthy movement occupies an optimal zone of variability, and that pathology pushes movement either toward excessive randomness or excessive regularity. The MCR signature observed here, with both elevated variability and reduced complexity, fits the picture of a neuromotor system that has lost fine-grained regulation. It also aligns with neuroimaging work linking MCR to cortical atrophy and white matter hyperintensities, since the brain networks that support executive function and attention are deeply involved in orchestrating the moment-to-moment regulation of gait fluctuations.

The clinical implications are considerable. Because the anomaly scores are computed per domain and per individual, they could function as personalized, interpretable digital biomarkers. A clinician could, in principle, see not just that a patient’s gait is abnormal, but which specific control processes are deviating from the healthy reference and by how much. That granularity matters for early detection, since the MCR signature identified here was visible even in a modest sample of twenty affected individuals, and it matters for monitoring, because domain-specific scores could in future studies track whether an intervention is restoring healthy gait dynamics rather than merely speeding someone up. The treadmill protocol itself, two short bouts at preferred speed with trunk-worn accelerometry, is simple enough to imagine translating into routine geriatric assessment.

Important caveats remain. The study is cross-sectional, so it demonstrates association rather than prediction; it cannot yet say whether the multidimensional signature precedes cognitive decline or emerges alongside it. The MCR group is small, and treadmill walking, while well controlled, differs in known ways from overground walking. The authors note that data are available from the corresponding author upon reasonable request, and the study, conducted within the PRESAGE project in Normandy with support from European and regional funders, was designed with the kind of immersive and instrumented facilities that allow unusually rich movement recording. Whether the anomaly-detection framework generalizes to community-based cohorts and to overground or free-living walking will be the decisive test.

Even so, the study marks a conceptual shift in how the field might think about the motor face of cognitive risk. Gait speed tells you that something may be wrong; the temporal architecture of movement fluctuations begins to tell you what. If subsequent longitudinal work confirms that the complexity and stability domains identified here predict conversion to major neurocognitive disorders ahead of conventional markers, the humble act of walking a few minutes on a treadmill, read through the right mathematical lens, could become one of the most accessible windows into the aging brain that medicine currently possesses.

Subject of Research: Multidimensional gait analysis and anomaly detection for identifying motoric cognitive risk syndrome in older adults

Article Title: Beyond gait speed: a multidimensional motor signature of motoric cognitive risk syndrome identified through domain-specific anomaly detection

Article References: Perthuy, B., Vinzant, H., Brifault, C., Cabibel, V., Laillier, R., Sultan, A., Denise, P., Lefèvre, N., Dalibot, A., Stergiou, N., Cignetti, F., & Decker, L. M. (2026). Beyond gait speed: a multidimensional motor signature of motoric cognitive risk syndrome identified through domain-specific anomaly detection. GeroScience. https://doi.org/10.1007/s11357-026-02493-4

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02493-4

Keywords: motoric cognitive risk syndrome, gait analysis, gait speed, gait variability, nonlinear dynamics, anomaly detection, Gaussian mixture model, digital biomarkers, dementia risk, older adults, GeroScience, treadmill walking

The team drew on an unusually rich data infrastructure. Using the Centers for Medicare and Medicaid Services Chronic Conditions Data Warehouse, they identified beneficiaries aged 65 and older who were alive and Alzheimer’s-free in 2011 and then tracked whether claims-coded Alzheimer’s disease appeared between 2012 and 2016. After excluding movers, people who died or could not be linked across the follow-up window, and those with prevalent disease at baseline, the analytic cohort comprised 181,614 residents of Miami-Dade County, of whom 7,606, or about 4.2 percent, developed claims-identified Alzheimer’s disease during follow-up. Each beneficiary’s residential Census block was linked to vegetation measurements derived from Landsat satellites, the workhorse of long-term environmental monitoring, and models adjusted for age, sex, race and ethnicity, neighborhood median household income, and neighborhood walkability measured by Walk Score.

The core exposure metric was the Normalized Difference Vegetation Index, or NDVI, a spectral index computed from the contrast between how vegetation absorbs red light for photosynthesis and scatters near-infrared radiation from its internal leaf structure. Higher NDVI values indicate denser, more photosynthetically active vegetation, and the index has become the default greenness measure in health studies because it is reproducible, spatially continuous, and available in archives stretching back decades. Yet NDVI has well-known limits: it measures photosynthetic activity, not tree canopy, park quality, accessibility, or vegetation type, and it says nothing about whether residents actually use the green spaces near them. The new study adds another layer of caution by showing that even the numerical value of NDVI assigned to a neighborhood depends heavily on choices researchers make before the analysis begins.

Those choices fall into two categories that geographers have long formalized as the modifiable areal unit problem and the modifiable temporal unit problem. The first, known as MAUP, recognizes that statistical relationships can change when data are aggregated at different spatial scales or zoning systems. The second, MTUP, is its temporal analogue: results can shift depending on how measurements are segmented and averaged across time. Both problems are textbook material in spatial epidemiology, but they had rarely been tested systematically for a chronic neurodegenerative outcome. The Miami-Dade team did exactly that, generating 32 distinct NDVI products by combining four raster resolutions (30, 120, 250, and 500 meters), two temporal acquisition strategies (single-date imagery versus seasonal composites averaging all cloud-free September-to-November scenes), two temporal specifications (2011 baseline versus a 2011-plus-2016 sum), and two metrics (mean NDVI and NDVI range within each block).

The headline result was reassuring in direction but revealing in detail. Across all four spatial resolutions, higher seasonal mean NDVI in 2011 was consistently associated with lower odds of incident Alzheimer’s disease. Each 0.1-unit increase in NDVI was linked to roughly 18 to 23 percent lower odds, with the strongest association at the 250-meter resolution, where the odds ratio was 0.77. Notably, the native 30-meter Landsat resolution, the finest available, did not produce the best-fitting models; moderate aggregation at 120 and 250 meters captured neighborhood-scale greenness more consistently, apparently by smoothing pixel-level noise while retaining meaningful local variation. The researchers used the Quasi-likelihood under the Independence Model Criterion, a generalization of the Akaike Information Criterion for their clustered regression framework, to compare model fit, and the 250-meter seasonal model scored best within its set, though neighboring resolutions performed similarly.

Temporal aggregation mattered just as much. When the team used a single cloud-free image from fall 2011 instead of the seasonal composite, the inverse association weakened considerably, with odds ratios closer to 0.92 to 0.96 per 0.1-unit NDVI increase. Seasonal compositing, the authors argue, reduces the influence of anomalous acquisition dates, residual cloud and atmospheric contamination, and short-term vegetation fluctuations, all of which are especially relevant in subtropical Miami where cloud-free imagery is scarce. In a striking contrast, the single-date models fit best at the finest 30-meter resolution, while the seasonal models favored moderate aggregation, suggesting that the apparent spatial scale of a greenness effect depends on how the exposure is captured in time. A two-time-point metric combining 2011 and 2016 NDVI confirmed that the spatial pattern of associations was robust, though it was interpreted strictly as a sensitivity analysis because the 2016 measurement postdates some incident cases.

The study also probed an exploratory metric with a very different personality: NDVI range, the difference between the maximum and minimum pixel values within each Census block. Whereas mean NDVI was consistently protective, higher NDVI range was generally associated with higher Alzheimer’s incidence, and the association was fragile, weakening or disappearing at coarser resolutions. The authors are careful to note that range is not a measure of greenspace fragmentation, connectivity, or landscape morphology; it is simply a crude indicator of within-block spectral variability that is highly sensitive to extreme pixels and to the number of pixels available. Still, its positive association hints that heterogeneous residential environments, where lush vegetation coexists with sparse cover, may tell a different story than uniformly green blocks, a question that will require proper landscape-configuration metrics to resolve.

Why should anyone outside the remote-sensing community care? Because the greenness–health literature is increasingly cited in urban planning debates, from tree-planting initiatives to heat mitigation programs, and because prior studies in this very field have reached conclusions using wildly different exposure definitions. Some used 300-meter buffers, others Census blocks or road-network buffers; some used a single satellite image, others annual averages or multi-year moving windows. Reviews have found that buffer sizes in published studies range from about 30 to 5,000 meters. The new analysis shows that holding the population, outcome, covariates, and statistical model constant while varying only the exposure definition changes both the magnitude of the effect and which model fits best. Scale selection, the authors conclude, is not a technical preprocessing detail but a substantive component of epidemiologic inference that should be tested and reported explicitly.

The authors are equally candid about the study’s limits. Alzheimer’s status came from insurance claims rather than clinical adjudication, so delayed diagnosis, underdiagnosis, and coding variation are possible, though such misclassification would likely attenuate rather than inflate the observed associations. Residential Census blocks capture where people live, not where they walk, socialize, or spend their days, a limitation known as the Uncertain Geographic Context Problem. The cohort excluded movers and people with incomplete address linkage, potentially producing a more residentially stable and healthier sample than the county at large. Walk Score data from 2013 were assigned to 2011 residences, and the analysis did not adjust for air pollution, heat, or noise, which correlate with greenness and may independently affect cognitive health. The observed associations therefore reflect residential greenness within a broader urban environmental context rather than isolated effects of vegetation alone.

Even so, the practical message is clear and, in its way, empowering. NDVI remains a valuable, scalable screening tool for identifying neighborhoods where low greenness coincides with older-adult vulnerability, and the protective signal itself survived every scale test the researchers threw at it. But translating a satellite index into a greening prescription requires more: information on tree canopy versus grass, vegetation type, park access, safety, land ownership, and community priorities. Future work, the authors suggest, should pair higher-frequency satellite products such as MODIS or harmonized Landsat-Sentinel data with mobility-aware exposure measures and policy-actionable greenspace indicators. In the meantime, the study stands as a reminder that in environmental epidemiology, the map you choose to draw helps determine the world you find.

Subject of Research: Spatial and temporal scale sensitivity of satellite-derived NDVI greenness exposure assessment in relation to Alzheimer's disease incidence among older Medicare beneficiaries

Article Title: Spatial and Temporal Scale Sensitivity in NDVI-Based Greenness Exposure Assessment for Alzheimer’s Disease Incidence: A Miami-Dade County Medicare Cohort Study

Article References: Southworth, J., Chaudhary, A., Dewald, J. R., Ma, R., Safaei, M., Szapocznik, J., & Brown, S. C. (2026). Spatial and Temporal Scale Sensitivity in NDVI-Based Greenness Exposure Assessment for Alzheimer’s Disease Incidence: A Miami-Dade County Medicare Cohort Study. Environmental Advances, Article 100765. https://doi.org/10.1016/j.envadv.2026.100765

Image Credits: AI Generated

DOI: 10.1016/j.envadv.2026.100765

Keywords: Alzheimer's disease, NDVI, greenness exposure, remote sensing, Medicare cohort, modifiable areal unit problem, modifiable temporal unit problem, Landsat, spatial epidemiology, urban green space, Miami-Dade County, dementia risk

The rationale for the study rests on a well-documented but poorly understood phenomenon. As people age, total cerebral blood flow and the brain vessels’ ability to respond to metabolic demands both decline, and these declines independently predict higher dementia risk even after accounting for other cardiovascular factors. At the same time, aging vasculature accumulates oxidative stress, an imbalance between reactive oxygen species and the body’s antioxidant defenses. Excess reactive oxygen species degrade nitric oxide, the signaling molecule that blood vessel linings use to relax and widen. If oxidative stress is indeed strangling the aging brain’s arteries, then flooding the system with a potent antioxidant should, in principle, loosen the grip.

To test that idea, the team recruited generally healthy young adults aged 18 to 29 and middle-aged and older adults aged 55 to 79 from the Newark, Delaware area, excluding smokers, pregnant or breastfeeding women, and anyone with cardiovascular, neurological, autoimmune, or major psychiatric conditions. Each participant completed two laboratory visits separated by at least four days, receiving an intravenous ascorbic acid infusion on one occasion and a saline placebo on the other, in a randomly assigned order. The dosing protocol, adapted from earlier vascular aging studies, delivered a priming bolus of 0.06 grams of vitamin C per kilogram of fat-free mass over 20 minutes, followed by a continuous drip of 0.02 grams per kilogram maintained until all post-infusion measurements were complete. In a small subset where blood samples survived analysis, serum vitamin C levels rose roughly sevenfold, from about 1.2 to 8.6 milligrams per deciliter, confirming the infusion pushed concentrations well above physiological norms.

The study’s centerpiece was a clever probe of cerebrovascular endothelial function. When carbon dioxide in the blood rises abruptly, vessels downstream of the internal carotid artery dilate, increasing turbulent flow and shear stress along the carotid wall. That shear stress triggers the endothelium to release nitric oxide, which widens the artery further. By using a dynamically controlled gas delivery system to raise participants’ end-tidal carbon dioxide by 9 millimeters of mercury for just 30 seconds, and imaging the internal carotid artery with high-resolution duplex ultrasound, the researchers could quantify how well the extracranial vessel lining responded to a nitric oxide–dependent stimulus. Before infusion, this response was significantly blunted in the older group: relative internal carotid artery reactivity averaged about 3.4 percent in young adults versus roughly 3.0 percent or lower in the middle-aged and older group, with the deficit most pronounced in the vitamin C visit’s baseline measurements.

After the vitamin C infusion, the picture changed markedly for the older participants. Their relative internal carotid artery reactivity rose significantly, and the absolute diameter change climbed from a mean of about 0.056 millimeters to 0.32 millimeters, effectively erasing the age gap with the young group. In striking contrast, the same participants showed no such improvement after saline, and the young adults’ responses were essentially flat regardless of which infusion they received. This pattern, improvement only where function was impaired, is exactly what the pharmaco-dissection approach predicts if oxidative stress is suppressing nitric oxide–mediated dilation in aged vessels. Notably, the carbon dioxide stimulus itself was matched across conditions, with end-tidal changes of roughly 8 to 9 millimeters of mercury in every group and time point, so the differences could not be attributed to unequal challenges.

The researchers also examined the middle cerebral artery, an intracranial vessel whose response to sustained, three-minute hypercapnia is far less dependent on nitric oxide. Using transcranial Doppler ultrasound, they measured blood velocity and, by normalizing to beat-by-beat mean arterial pressure, calculated cerebrovascular conductance. At baseline, older adults showed significantly lower conductance-based reactivity than young adults. Vitamin C infusion again improved middle cerebral artery reactivity in the older group, whether expressed as velocity change or conductance change, while saline did not. The authors suggest this intracranial effect likely operates through different pathways than the carotid response, potentially involving pH regulation, red blood cell ATP release, potassium and calcium channels, prostaglandins, or reactive oxygen species acting directly as vasodilators. The precise mechanism, they caution, remains unresolved.

Not every measurement cooperated with the tidy narrative. Total cerebral blood flow, estimated from internal carotid and vertebral artery flows, was unexpectedly higher in the older group than the young group before infusion, contradicting the large body of literature showing age-related declines. The authors note that women in their sample, who tend to have higher cerebral blood flow, made up 71 percent of the older subgroup with usable data versus 44 percent of the young subgroup, and that global flow estimates cannot capture regional perfusion differences. Vitamin C did not significantly alter total cerebral blood flow in either age group. Meanwhile, brachial artery flow-mediated dilation, the standard test of peripheral endothelial function, was lower in older adults at baseline but showed only a non-significant trend toward improvement after vitamin C. In a small subset with paired data, peripheral and cerebral endothelial responses were uncorrelated, suggesting the two beds reflect distinct endothelial physiology and should not be treated as interchangeable windows on vascular health.

The study’s limitations are considerable and the authors are candid about them. Sample sizes were small and varied across outcomes, with complete internal carotid data available for only 10 to 11 participants per infusion visit and middle cerebral artery data for 17 to 20. A freezer malfunction destroyed most serum samples, preventing direct measurement of oxidative stress markers or nitric oxide metabolites in the full cohort, which means the proposed mechanism remains inferential. The transcranial Doppler technique assumes the middle cerebral artery does not itself dilate during hypercapnia, an assumption challenged by MRI studies. No comparable vasodilatory control condition was included, so the effect cannot be definitively pinned to nitric oxide–dependent pathways. And the analysis relied on pre-specified contrasts without multiple-testing correction, appropriate for hypothesis-driven designs but demanding cautious interpretation.

Even with those caveats, the central result stands out for its clarity: antioxidant-responsive mechanisms appear to be implicated in age-related impairments of both extracranial and intracranial cerebrovascular reactivity. The authors are careful to stress that this was a mechanistic experiment, not a therapy trial, and that nothing in the data supports self-treatment with high-dose vitamin C. Oral supplementation cannot reproduce the serum concentrations achieved intravenously, and whether repeated infusions would produce lasting benefit, or whether improved reactivity translates into preserved cognition, are questions for future studies with larger and more diverse cohorts. What the trial does establish is a model: a safe, reversible intervention that selectively restores cerebrovascular function in older adults, giving researchers a tool to dissect the redox pathways that may one day be targeted to keep aging brains well perfused.

Subject of Research: Effects of intravenous ascorbic acid infusion on age-related cerebrovascular dysfunction in adults

Article Title: Supraphysiological ascorbic acid infusion attenuates cerebrovascular dysfunction in middle‐aged and older adults

Article References: DeConne, T. M., Sanjana, F., Habash, E. M., Decker, K. P., Nichols, W., Hobson, J. C., Rizzi, N. A., & Martens, C. R. (2026). Supraphysiological ascorbic acid infusion attenuates cerebrovascular dysfunction in middle‐aged and older adults. Physiological Reports, 14(19), Article e71120. https://doi.org/10.14814/phy2.71120

Image Credits: AI Generated

DOI: 10.14814/phy2.71120

Keywords: ascorbic acid, cerebrovascular reactivity, vascular aging, oxidative stress, nitric oxide, cerebral blood flow, internal carotid artery, middle cerebral artery, hypercapnia, endothelial function, dementia risk, randomized crossover trial

The study was retrospective in design, meaning the researchers looked back at imaging data that had already been collected rather than recruiting participants prospectively. The team analyzed brain MRIs from 2,826 patients, 1,094 men and 1,732 women, ranging in age from 18 to 96 years. The neuroimaging data came from consecutive inpatient and outpatient clinical MRI examinations performed at the University of Wisconsin Hospitals and Clinics and at community partner sites between January 2024 and June 2024. Importantly, patients with imaging evidence of disease were excluded from the analysis, which helps ensure that the brain differences observed were not simply the result of an existing neurological diagnosis.

To quantify neighborhood disadvantage, the researchers calculated an Area Deprivation Index, or ADI, score for each patient based on the resident’s zip code. The ADI is a census block group-level composite measure that incorporates 17 indicators spanning income, education, employment, and housing characteristics, derived from 2023 American Community Survey data. Because the index aggregates information about the socioeconomic character of an entire residential area rather than any single individual, it captures something broader than personal circumstances alone. Researchers have increasingly turned to indices like the ADI in health disparities research because they reflect accumulated structural conditions, including poverty concentration, housing instability, and limited local resources, that extend beyond individual behaviors.

The study focused on two key brain health metrics. The first was the brain age gap, the difference between a person’s chronological age and how much younger or older their brain appears based on estimates derived from MRI scans. Machine-learning approaches to brain age estimation have become a widely used tool in neuroimaging research, because a brain that appears older than its owner’s actual age is thought to reflect accumulated wear on brain tissue. The second metric was total brain volume, normalized to intracranial volume so that head size would not confound the comparison. Statistical models were controlled for age and sex, two of the strongest determinants of brain structure, to isolate the contribution of neighborhood disadvantage.

The results were striking. Individuals living in the most disadvantaged neighborhoods exhibited a higher brain age gap, meaning their brains appeared older than their chronological years, and lower total brain volume than residents of less deprived areas. We’ve long suspected that your living environment affects your brain, but until now it’s not been proven at scale in clinical populations, said John-Paul J. Yu, M.D., Ph.D., associate professor of radiology, psychiatry, biomedical engineering and biostatistics and medical informatics at the University of Wisconsin School of Medicine and Public Health, and an associate director at the Center for Health Disparities Research at the University of Wisconsin–Madison. We’ve shown very robust, measurable metrics that our living environment has an outsized impact on the brain at the molecular and cellular level.

Yu emphasized the everyday significance of the finding. We found that residents in the most disadvantaged neighborhoods had an accelerated brain age compared with people living in less deprived areas, he said. In other words, where you live leaves a measurable imprint on your brain. Elevated brain age is not merely a statistical curiosity. Previous research has linked a higher brain age gap to cardiovascular risk factors, psychiatric illness, and cognitive impairment, making it a potential early warning sign of declining neurological health long before symptoms become clinically obvious.

The MRI analysis also revealed a second, equally consequential difference: residents of the most disadvantaged neighborhoods had higher volumes of white matter hyperintensities. These are bright spots that appear on certain MRI sequences and are widely regarded as markers of small-vessel damage in the brain. White matter hyperintensities are essentially the footprints of cardiovascular damage in the brain, Yu explained. When you live with chronic stressors like high blood pressure, poor sleep or constant stress, blood vessels constrict, restricting blood flow to that part of the brain. Over time, these areas show up as these bright spots on MRI. Larger white matter hyperintensity volumes are connected to a higher risk of memory loss, cognitive problems, and dementia, which places this imaging finding squarely within the pathway linking environmental hardship to long-term neurological disease.

The biological logic behind these associations is consistent with a growing body of research on the health effects of chronic stress and deprivation. Prolonged exposure to environmental stressors is known to elevate blood pressure, disrupt sleep, and sustain inflammatory processes, all of which can damage the small blood vessels that nourish deep brain tissue. When those vessels narrow or fail, the surrounding white matter is starved of adequate perfusion and gradually shows the damage that radiologists recognize as hyperintensities. At the same time, sustained adversity may accelerate the loss of brain tissue volume that normally accompanies aging. The new study suggests that these processes are not evenly distributed across the population but instead track with the socioeconomic character of the places where people live.

Yu said the findings suggest that data derived from MRI may serve as intermediate imaging biomarkers of structural inequity, with relevance for both population neuroscience and clinical risk stratification. In practical terms, that means radiologists and clinicians could one day use routinely acquired brain scans, combined with neighborhood-level indices such as the ADI, to identify individuals and communities at elevated risk of cognitive decline before disease manifests. We have shown for the first time in a real-world clinical population that an individual’s environment has clear, quantifiable implications for brain age, and, by proxy, brain health, he said. The conditions in which individuals are born, live, work and age, profoundly shape long-term neurological health outcomes.

The implications extend well beyond the radiology suite. Neighborhood disadvantage, quantified by indices such as the ADI, is an important determinant because it reflects accumulated structural inequities extending beyond individual behaviors that contribute to disparities in clinical outcomes, Yu noted. It’s important to factor in this data when planning health intervention programs, crafting public policy, and identifying geographically defined areas that need improved access to care. As an emerging area of research with critical implications for basic science, public health, and clinical practice, the work points toward a future in which brain imaging not only diagnoses disease but also illuminates the social conditions that quietly shape it. The study, titled Evaluating the Effect of Neighborhood-level Disadvantage on Brain Health: An Imaging Epidemiology Study, was published on September 15, 2026, with collaborators including Ethan H. Willbrand, Elizabeth M. Stoeckl, Daryn Belden, Sheena Y. Chu, Eleanna M. Melcher, Daniil Zhitnitskii, Elena Bonke, Jussi Mattila, Usman Iftikhar, Juha Koikkalainen, Antti Tolonen, Jyrki Lötjönen, and Richard Bruce.

Subject of Research: The association between neighborhood-level socioeconomic disadvantage and brain health measured by MRI

Article Title: Where you live may influence your brain health

Article References: Where you live may influence your brain health. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: brain health, neighborhood disadvantage, Area Deprivation Index, brain age gap, MRI, white matter hyperintensities, total brain volume, health disparities, Radiology, dementia risk, public health, neuroimaging

The study, led by Kaitlin Casaletto, PhD, an associate professor at the UCSF Fein Memory and Aging Center, and co-senior author Rowan Saloner, PhD, also of the Fein Memory and Aging Center, focused on molecules circulating in the blood that are known to be linked to brain aging. Using a commercially available research blood test that measures more than a hundred such molecules, the team identified 16 whose levels changed in a coordinated way as women moved through menopause. Crucially, these molecular shifts tracked more closely with changing hormone levels than with chronological age, indicating that it was the hormonal upheaval of menopause itself — not simply the passage of time — that was driving the changes.

The implications are striking because two-thirds of people with Alzheimer’s disease are women, a disparity that cannot be explained by women’s longer average lifespans alone. Despite decades of research, scientists have struggled to pinpoint exactly what it is about women’s biology that makes them more vulnerable to dementia. The new findings point toward a compelling answer: the earliest brain changes associated with Alzheimer’s disease begin decades before symptoms appear, and for women, the biology of menopause may help set the stage for that process in midlife.

To capture the transition with unusual precision, the researchers recruited 80 women in their 40s and 50s and used a staging tool called STRAW+10, which combines reported symptoms with hormone measurements to determine exactly where each woman stood in the menopause transition. First author Madeline Wood Alexander, a graduate student at the University of Toronto, emphasized why this mattered. Many studies simply ask women whether they have gone through menopause and when, she noted, but her team wanted to capture the years of hormonal flux that unfold before and after the final menstrual period. Menopause is not a single moment; symptoms and hormone changes can begin as early as a decade before the last cycle and persist for years afterward, typically with the final period occurring around age 51.

What the team found was a coherent molecular fingerprint of the transition. Molecules associated with inflammation tended to rise as estradiol, the primary estrogen, declined. A separate group of molecules tied to Alzheimer’s disease biology rose in step with follicle-stimulating hormone, or FSH, which surges as the ovaries wind down. The pattern was not confined to the small UCSF cohort: when the researchers analyzed previously collected data from more than 2,800 women in the UK Biobank, they replicated the same molecular shifts, strengthening the case that this fingerprint is a general feature of the menopause transition rather than an artifact of one group of participants.

The most consequential discovery came when the scientists looked at the same molecules in older women. Drawing on data from nearly 12,000 women in their 60s and early 70s across four previous studies, they found that those with the highest levels of the menopause-linked molecules performed worse on memory and thinking tests and faced a 15 percent higher risk of developing Alzheimer’s disease as they aged. In other words, the molecular signature written during the hormonal turbulence of midlife appeared to remain legible in the blood decades later, and it correlated with real differences in cognition and disease risk. Saloner described the significance plainly: the team is identifying molecular shifts in blood in midlife postmenopausal women that also predict cognition later in life, making these molecules important markers of both menopause and cognitive aging.

One of the most intriguing findings involved vasomotor symptoms. Women who reported night sweats tended to show greater increases in inflammatory molecules during the transition, and that link proved remarkably durable. Older women who recalled having hot flashes during menopause still carried higher levels of those inflammatory markers years afterward. This suggests that the intensity of a woman’s menopausal symptoms may carry information about her underlying biology — not just her comfort in the moment, but potentially her long-term brain health trajectory. It is a finding that reframes symptoms often dismissed as a natural nuisance into potential clinical signals worth measuring.

The researchers are careful about what the study does and does not show. The findings are correlational, and the team does not yet know what brain changes or dementia risk factors the menopause transition may directly trigger. Casaletto stressed that the scientists do not think menopause is directly causing dementia. Rather, she explained, it may become possible to predict a woman’s risk for dementia decades later by measuring the levels of these molecules around the time of menopause. There is also a complicating observation: in a small sample of midlife men, much of the molecular fingerprint looked the same as it did in postmenopausal women. That hints that menopause may trigger a rapid shift in biological aging that unfolds far more gradually in men, raising new questions about how sex-specific reproductive biology and general aging processes intersect.

The long-term ambition is a familiar one drawn from cardiology: a routine blood test that works for dementia risk the way cholesterol panels work for heart disease. Such a test could identify women in midlife who might benefit from early interventions — whether lifestyle changes, monitoring, or eventually targeted therapies — long before any cognitive symptoms emerge. Casaletto argues that midlife is a critical window for both men and women, a period in which the brain can be set up to be more resilient or more vulnerable to dementia in later life. For women, she said, menopause may be an especially powerful time to intervene. Wood Alexander added an important framing note: menopause is a normal physiological process that everyone with ovaries who lives long enough will experience, and it should be viewed not as something bad but as an opportunity to understand and perhaps modify the biology of brain aging in women.

The science is now moving from cross-sectional snapshots to longitudinal observation. Casaletto, in collaboration with scientists around the country, is launching the Longitudinal Menopause Project, which will enroll its first participants and follow women through the entire menopause transition with twice-yearly blood draws, brain MRI scans, cognitive testing, wearable devices, and smartphone-based monitoring. Separately, Wood Alexander is recruiting women at the University of Toronto to measure molecular changes throughout menopause. Together, these efforts aim to confirm whether the 16-molecule fingerprint truly predicts individual outcomes, to disentangle which hormonal changes drive which molecular shifts, and to determine whether interventions during the transition can alter the trajectory. If they succeed, the years around a woman’s final menstrual period — long treated as an awkward gap in medical research — could become one of the most valuable early-warning checkpoints in the prevention of Alzheimer’s disease.

Subject of Research: Blood molecular changes during the menopause transition and their association with later-life cognitive decline and Alzheimer's disease risk

Article Title: Menopause leaves a fingerprint that may predict dementia risk

Article References: Menopause leaves a fingerprint that may predict dementia risk. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: menopause, Alzheimer's disease, dementia risk, blood biomarkers, estradiol, follicle-stimulating hormone, brain aging, inflammation, cognitive decline, UK Biobank, women's health, UCSF

Natural menopause occurs when menstrual periods stop permanently without surgery, chemotherapy, or other medical intervention. Although menopause typically occurs later in life, premature menopause is generally defined as occurring before age 40, while early menopause occurs between ages 40 and 45. The new study used a broader research definition of early natural menopause, including women whose menopause occurred before age 48. These conditions affect an estimated 6% of women worldwide and have previously been linked to increased risks of cardiovascular disease, dementia, and premature death.

The researchers analyzed health and social data from nearly 20,000 women with early natural menopause. Rather than examining a single social factor in isolation, they created a cumulative measure based on 14 social determinants of health. Participants were then classified into favorable, intermediate, or unfavorable groups according to their overall social circumstances. This approach was designed to capture the reality that disadvantage rarely occurs one factor at a time: unemployment may coincide with lower income, unstable housing, limited education, reduced access to healthcare, and chronic psychosocial stress.

Social determinants of health include the conditions in which people are born, grow up, learn, work, live, worship, spend leisure time, and age. These circumstances can influence exposure to stress, environmental hazards, health information, nutritious food, preventive medicine, and high-quality medical care. They can also shape whether a person is able to follow treatment recommendations or obtain timely evaluation for symptoms. By combining multiple determinants into a single risk profile, the researchers sought to measure the cumulative biological and social pressure that may influence health after early menopause.

Participants were followed for a median of 10.8 years, allowing the investigators to examine health outcomes over a substantial period. The analysis showed that women in more disadvantaged social circumstances experienced significantly worse health trajectories than those with more favorable circumstances. Their risks were elevated for all-cause mortality, meaning death from any cause, and for cardiovascular disease, which includes conditions affecting the heart and blood vessels. The study also identified a pronounced association between cumulative disadvantage and incident dementia, referring to newly diagnosed disease during follow-up.

Among the 14 social variables examined, unemployment showed the strongest independent association with both all-cause mortality and incident dementia. The finding does not establish that unemployment directly causes either outcome, but it highlights employment status as a potentially important marker of broader economic and psychological strain. Loss of work can reduce income, health insurance, social connection, daily structure, and access to services. Long-term unemployment may also contribute to chronic stress and depression, biological processes that have been associated with inflammation, impaired cardiovascular health, and cognitive decline.

Early loss of ovarian function may provide part of the biological context for these findings. Estrogen influences vascular function, lipid metabolism, bone health, and several processes involved in brain maintenance. When estrogen exposure declines earlier than expected, women may spend more years with potential vulnerability to cardiovascular and neurological disease. Social adversity could intensify that vulnerability through factors such as hypertension, poor sleep, chronic inflammation, smoking, limited physical activity, or delayed medical care. The study’s results suggest that biological risk and social conditions may interact rather than operate independently.

The researchers found no significant association between the social-determinants-of-health measures and incident cancer in this group. That contrast is important because it indicates that the effects of social disadvantage were not uniform across every major health outcome. The results instead point to a particularly strong relationship with mortality, cardiovascular disease, and dementia. Because the study was observational and based on statistical associations, the findings cannot prove a direct causal pathway. Differences in health behaviors, access to treatment, pre-existing illness, and other unmeasured factors may also have influenced the results.

The authors argue that social history should become a routine component of care for women with premature or early menopause. A clinical assessment could include employment and financial security, education, housing, transportation, social support, access to healthcare, and exposure to discrimination or chronic stress. Identifying these issues early could help clinicians connect patients with cardiovascular screening, mental-health services, employment or social assistance, and strategies to protect cognitive health. “Disrupting this complex interaction will require a routine, comprehensive assessment of social determinants of health as a fundamental principle” in menopause care, said Stephanie Faubion, medical director for The Menopause Society. The study underscores that early menopause is not only a reproductive milestone but also a potential signal for long-term health monitoring—especially when it occurs alongside persistent social disadvantage.

Subject of Research: People

Article Title: Combined social determinants of health, mortality, and adverse health outcomes in early natural menopause

News Publication Date: 12-Aug-2026

Web References: https://menopause.org; https://menopause.org/wp-content/uploads/press-release/MENO-D-26-00058.pdf

References: Menopause. DOI: 10.1097/GME.0000000000000002866

Keywords: early natural menopause, premature menopause, social determinants of health, unemployment, cardiovascular disease, dementia, mortality, women’s health, socioeconomic disadvantage, healthy aging